Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.
Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.
复制标题
DOI：
10.1371/journal.pone.0045127
复制
发表时间：
2012
期刊：
影响因子：
3.7
通讯作者：
Sohn J
中科院分区：
文献类型：
--
作者：
Jung M;Koo JS;Moon YW;Park BW;Kim SI;Park S;Lee SH;Hong S;Rha SY;Chung HC;Kim JH;Sohn J
通过这项研究，我们旨在验证几种已知可能预测曲妥珠单抗和紫杉醇 (TP) 结果的生物标志物。本研究纳入2006年至2009年在单一机构接受TP治疗的人表皮生长因子2（HER2）阳性转移性乳腺癌（MBC）患者。对于获得的福尔马林固定石蜡包埋的肿瘤组织，评估 HER2 扩增指数 (AI) 和免疫球蛋白 G 片段 C 受体 (FCGR) 的多态性作为曲妥珠单抗的生物标志物，并评估 III 类 β 微管蛋白 (bTubIII) 的表达作为紫杉醇的预测因素。在 46 名接受 TP 治疗的患者中，27 名患者可以评估 HER2 AI，31 名患者可以评估 bTubIII，26 名患者可以评估 FCGR 基因多态性。 HER2 AI 的中位数为 5.0（范围，1.4−15.5），较高的 HER2 AI（≥5.0）与更好的缓解率（RR）（80% vs. 42%，P = 0.049）和更长的无进展生存期（PFS）（13.6 vs. 6.9 个月，P = 0.023）显着相关。高 bTubIII 表达的 RR 高于低表达的 RR（81% vs. 40%，P = 0.040），并且 PFS 更长（16.2 个月 vs. 8.8 个月，P = 0.04）。然而，FCGR 2A-H131R 或 FCGR 3A-V158F 的多态性不能预测 RR 或 PFS。我们的结果表明，高 HER2 AI 和高 bTubIII 表达可以预测 TP 治疗的结果，但没有发现 FCGR 多态性方面的证据。
Through this study, we aimed to validate several biomarkers that have been known to possibly predict the outcomes of the trastuzumab and paclitaxel (TP). Human epidermal growth factor 2 (HER2) positive metastatic breast cancer (MBC) patients who had been treated with TP in single institute from 2006 to 2009 were included in this study. For procured formalin fixed paraffin embedded tumor tissues, HER2 amplification index (AI) and polymorphisms of the immunoglobulin G fragment C receptors (FCGR) were assessed as biomarkers to the trastuzumab and expression of class III beta tubulin (bTubIII) was evaluated as a predictive factor to the paclitaxel. Of 46 patients treated with TP, 27 patients could be evaluated for HER2 AI, 31 for bTubIII, and 26 for FCGR gene polymorphism. The median of the HER2 AI was 5.0 (range, 1.4−15.5) and a higher HER2 AI (≥5.0) was significantly correlated with better response rate (RR) (80% vs. 42%, P = 0.049) and longer progression-free survival (PFS) (13.6 vs. 6.9 months, P = 0.023). High bTubIII expression showed higher RRs than did low expression (81% vs. 40%, P = 0.040) in addition to longer PFS (16.2 months vs. 8.8 months, P = 0.04). However, polymorphisms in FCGR 2A-H131R or FCGR 3A-V158F were not predictive of RR or PFS. Our results suggest that a high HER2 AI and high bTubIII expression could be predictive of the outcomes to TP therapy but no evidence was found in terms of FCGR polymorphisms.
登录
查看更多内容
影响因子：
254.7
作者：
Jemal, Ahmedin;Siegel, Rebecca;Thun, Michael J.
通讯作者：
Thun, Michael J.
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
2.2
作者：
Jiang, XM;Arepally, G;McKenzie, SE
通讯作者：
McKenzie, SE
影响因子：
50.5
作者：
Chang, H.;Rha, S. Y.;Chung, H. C.
通讯作者：
Chung, H. C.
影响因子：
45.3
作者：
Dawood, Shaheenah;Broglio, Kristine;Giordano, Sharon H.
通讯作者：
Giordano, Sharon H.